The estimated Net Worth of Thomas Hofstaetter is at least $424 Thousand dollars as of 18 March 2015. Thomas Hofstaetter owns over 70,000 units of Geron stock worth over $423,916 and over the last 15 years Thomas sold GERN stock worth over $0.
Thomas has made over 2 trades of the Geron stock since 2015, according to the Form 4 filled with the SEC. Most recently Thomas exercised 70,000 units of GERN stock worth $88,200 on 18 March 2015.
The largest trade Thomas's ever made was exercising 70,000 units of Geron stock on 18 March 2015 worth over $88,200. On average, Thomas trades about 11,667 units every 0 days since 2010. As of 18 March 2015 Thomas still owns at least 96,564 units of Geron stock.
You can see the complete history of Thomas Hofstaetter stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O GERON CORPORATION, 149 COMMONWEALTH DRIVE, SUITE 2070, MENLO PARK, CA, 94025.
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury, and Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Geron executives and other stock owners filed with the SEC include: